STAMFORD, Conn.--(BUSINESS WIRE)--SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat Combination with Belantamab Mafodotin
13:30
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc., (Nasdaq:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the completion of an in-depth operational review designed to extend the Company’s cash runway and deliver on its commitment to develop next-generation ADCs to bring more good days to patients and generate increased value for shareholders. Based on the outcomes of this review, the Company will prioritize continued develop
13:30
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced it will host “Sage FutureCast: An R&D and Portfolio Review” on Wednesday, July 24, 2019 from 8 a.m. to 9:30 a.m. EDT. Sage FutureCast will discuss the Company’s research and development strategy, and review clinical progress in programs throughout the depression, neurology and neuropsychiatr
13:30
WENDELSHEIM, Germany--(BUSINESS WIRE)--MODAG announced today the completion of a EUR 12 million Series A financing round, launching out of stealth mode to advance lead candidate anle138b into clinical development in Multiple System Atrophy (MSA). The company was founded in 2013 based on research conducted by Prof. Dr. Giese (Ludwig Maximilian University of Munich) and Prof. Dr. Griesinger (Max-Planck-Institute for Biophysical Chemistry) examining protein aggregation and its toxic properties in
12:00
米カリフォルニア州フォスターシティー & 上海--(BUSINESS WIRE)--（ビジネスワイヤ） -- Terns Pharmaceuticals, Inc.は本日、代謝疾患と肝臓関連疾患に対する革新的な治療／診断ソリューションの発見・開発に専心する後期段階のバイオ医薬品企業ジェンフィ（GNFT）との独占的なライセンス・協業契約を発表しました。契約の条件に従い、Ternsは大中華圏（中国本土、香港、マカオ、台湾）で非アルコール性脂肪肝炎（NASH）および原発性胆汁性胆管炎（PBC）の治療薬としてエラフィブラノールを開発・登録・販売する独占的権利を取得します。ジェンフィは3500万ドルの前払い金を受け取り、その後は臨床、規制関連、商業上のマイルストーン達成に基づき、最大1億9300万ドルの支払いを受け取る権利を得ます。また両社は協業してNASHおよびPBCの研究開発を前進させます。これら研究開発の対象には、ペルオキシソーム増殖因子活性化受容体アルファ／デルタ（PPAR α/δ）に対するデュアルアゴニストのエラフィブラノールと、Ternsの開発候補品の併用の可能性が含まれます。これ
11:35
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου